title: Does pulmonary rehabilitation give additional benefit over tiotropium therapy in primary care management of chronic obstructive pulmonary disease? Randomized controlled clinical trial in Hong Kong Chinese.
abstract: OBJECTIVE
  To evaluate whether multidisciplinary pulmonary rehabilitation programme (PRP) provides additional benefit over tiotropium therapy in managing chronic obstructive pulmonary disease (COPD) in primary care.
  
  
  METHODS
  A randomized controlled trial to analyse the difference in outcomes of COPD patients receiving tiotropium plus PRP vs. tiotropium treatment alone.
  
  
  METHODS
  Two primary care teaching clinics affiliated with a university which serves a population of 600,000.
  
  
  METHODS
  Fifty primary care COPD patients.
  
  
  METHODS
  Fifty subjects underwent spirometry and their status of COPD was confirmed by using the Vitalograph Gold Standard. They were then assessed by the 6-min walking distance (6MWD), Peak Visual Analogue Scale (Peak VAS) and Chronic Respiratory Disease Questionnaire (CRQ). All subjects were given tiotropium to optimize their treatment. After a 6-week period, half were randomized to the intervention group (i.e. receiving PRP), whereas the rest were randomized to control group which received only medication. Spirometry, 6MWD, Peak VAS and CRQ were performed in both groups at 6 weeks, 12 weeks and 3 months.
  
  
  RESULTS
  Spirometry, 6MWD, Peak VAS and CRQ.
  
  
  RESULTS
  Significant improvement (P < 0.05) was seen in 6MWD, symptoms of dyspnoea measured by Peak VAS and CRQ. The improvement was sustained at 3-month follow-up. However, no additional significant improvement was seen in the intervention group when compared with control.
  
  
  CONCLUSIONS
  Tiotropium therapy has improved health outcomes in COPD patients in primary care settings. A 6 weekly PRP did not give any additional benefits in patients already given tiotropium.
authors.affiliation: Family Medicine Unit, Department of Community and Family Medicine, The Chinese University of Hong Kong.
authors.forename: M
authors.initials: M
authors.lastname: Lindsay
authors.forename: A
authors.initials: A
authors.lastname: Lee
authors.forename: K
authors.initials: K
authors.lastname: Chan
authors.forename: P
authors.initials: P
authors.lastname: Poon
authors.forename: L K
authors.initials: LK
authors.lastname: Han
authors.forename: W C W
authors.initials: WC
authors.lastname: Wong
authors.forename: S
authors.initials: S
authors.lastname: Wong
mesh_terms: D000368:Aged; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D005081:Exercise Therapy; D005260:Female; D015438:Health Behavior; D006723:Hong Kong; D006801:Humans; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000523:psychology / Q000628:therapy; D012602:Scopolamine Derivatives / Q000627:therapeutic use*; D013147:Spirometry; D000069447:Tiotropium Bromide
chemical_list: D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide